Ysios Capital
Ysios Capital is a leading life sciences investor financing highly innovative companies worldwide
Business Model:
Revenue: $4.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Ysios Capital Information
Geographic Data
Address: Avenida de la Libertad, 25
City: Donostia-San Sebastian
State: barcelona
Zip: 20004
Country: ES
Financial Info
Stage:
Raised Last:
$0
Raised Total:$581M
Social
Twitter
Linkedin
Crunchbase
Metrics
1,171,675Website Global Rank
22,232Website Monthly Traffic
Twitter Followers
Description
Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages c.a. €350 M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2021 | Aura Biosciences | Post-IPO Equity | - |
| 10/2003 | TiGenix | Venture Round | 14M |
| 10/2013 | CVRx | Series F | 12M |
| 11/2016 | Corwave | Series B | 17.1M |
| 4/2021 | Synendos Therapeutics | Series A | 26.2M |
| 5/2017 | Anaconda BioMed | Series A | 16.9M |
| 9/2021 | Aelix Therapeutics | Venture Round | 0 |
| 10/2015 | Minoryx Therapeutics | Series A | 0 |
| 9/2010 | Cardoz | Series A | 17.6M |
| 3/2015 | Aura Biosciences | Series B | 0 |
| 10/2020 | SparingVision | Venture Round | 0 |
| 6/2012 | Inbiomotion | Series A | 2.5M |
| 9/2022 | SparingVision | Series B | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 9/2011 | AM Pharma | Series D | 39.9M |
| 10/2018 | Galecto | Series C | 90.2M |
| 2/2017 | Prexton Therapeutics | Series B | 31.1M |
| 3/2017 | Medlumics | Series B | 36.9M |
| 9/2014 | AM Pharma | Series E | 15.8M |
| 9/2020 | Splice Bio | Venture Round | - |
| 6/2019 | SANIFIT | Series D | 0 |
| 11/2013 | Endosense | Series C | 41.2M |
| 11/2017 | Xeltis | Series C | 53M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 12/2019 | Anaconda BioMed | Series B | 22.2M |
| 9/2010 | Sabirmedical | Venture Round | 6.5M |
| 6/2011 | STAT-Dx | Series A | 2.8M |
| 5/2018 | Rainier Therapeutics | Series B | 20M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 9/2015 | SANIFIT | Series C | 0 |
| 12/2011 | Medlumics | Series A | 4.7M |
| 2/2015 | Prexton Therapeutics | Series A | 10M |
| 4/2014 | Kala Pharmaceuticals | Series B | 0 |
| 4/2023 | ADCendo | Series A | 0 |
| 11/2012 | Endosense | Series C | 40.3M |
| 10/2020 | SparingVision | Series A | 52.7M |
| 5/2023 | VarmX | Series B | 0 |
| 1/2016 | Aelix Therapeutics | Series A | 12.5M |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 9/2020 | Galecto | Series D | 0 |
| 4/2021 | ADCendo | Series A | 61.8M |
| 5/2013 | STAT-Dx | Series B | 28.9M |
| 9/2018 | Minoryx Therapeutics | Series B | 0 |
| 9/2020 | Lava Therapeutics | Series C | 83M |
| 3/2017 | Rainier Therapeutics | Series B | 30M |
| 4/2016 | STAT-Dx | Series C | 0 |
| 7/2020 | VarmX | Series B | 36.3M |
| 6/2020 | Ona Therapeutics | Series A | 33.8M |
| 7/2017 | Babyscripts | Series A | 0 |
| 3/2020 | AM Pharma | Venture Round | 25.4M |
| 11/2016 | OxThera | Series D | 34.1M |
| 8/2019 | CVRx | Series G | 93M |
| 3/2016 | Inbiomotion | Series B | 0 |
| 3/2009 | BioVex | Venture Round | 40M |
| 10/2009 | Endosense | Series B | 0 |
| 5/2021 | Cytoki Pharma | Series A | 45M |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 5/2017 | Vivet Therapeutics | Series A | 41.2M |
| 5/2022 | Minoryx Therapeutics | Series C | 0 |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 9/2015 | DermaLumics | Venture Round | - |
| 1/2021 | Corwave | Series C | 43.2M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
| 5/2023 | VarmX | Series B | 0 |
| 4/2023 | ADCendo | Series A | 0 |
| 9/2022 | SparingVision | Series B | 0 |
| 6/2022 | Mineralys Therapeutics | Series B | 0 |
| 5/2022 | Minoryx Therapeutics | Series C | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 11/2021 | Aura Biosciences | Post-IPO Equity | - |
| 9/2021 | Aelix Therapeutics | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
